GLPG1690-CL-304 A Phase 3 randomized double blind parallel group, placebo controlled multicenter study to evaluate efficacy and safety of 2 doses of GLPG1690 in addition to local standard of care
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Galapagos NV
Start Date
May 6, 2019
End Date
April 30, 2023
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Galapagos NV
Start Date
May 6, 2019
End Date
April 30, 2023